Euroasian journal of hepato-gastroenterology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  14 (2024)
Volume  13 (2023)
Volume  12 (2022)
Volume  11 (2021)
Volume  10 (2020)
Volume  9 (2019)
Volume  8 (2018)
Volume  7 (2017)
Volume  6 (2016)
Volume  5 (2015)
Volume  4 (2014)
Volume  3 (2013)
Volume  2 (2012)
Volume  1 (2011)
Related articles

VOLUME 14 , ISSUE 2 ( July-December, 2024 ) > List of Articles

Original Article

Characterizing Nonalcoholic Fatty Liver Disease (NAFLD) in Lean Individuals at a Tertiary Care Hospital: A Cross-sectional Study

Shamim Nazir, Zaigham Abbas, Darayus P Gazder, Sania Maqbool, Shaukat Ali Samejo, Manesh Kumar

Keywords : Body mass index, Cardiometabolic risk factors, Insulin resistance, Lean non-alcoholic fatty liver disease, Metabolic dysfunction-associated steatotic liver disease, Metabolic dysfunction-associated fatty liver disease

Citation Information : Nazir S, Abbas Z, Gazder DP, Maqbool S, Samejo SA, Kumar M. Characterizing Nonalcoholic Fatty Liver Disease (NAFLD) in Lean Individuals at a Tertiary Care Hospital: A Cross-sectional Study. Euroasian J Hepatogastroenterol 2024; 14 (2):198-204.

DOI: 10.5005/jp-journals-10018-1452

License: CC BY-NC 4.0

Published Online: 27-12-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background: Fat accumulation in the liver is affecting 38% of the global population. It can also occur in normal-weight individuals, termed lean non-alcoholic fatty liver disease (NAFLD). This study examines Asian and Western body mass index (BMI) criteria, as well as metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) diagnostic guidelines, in lean fatty liver cases within a healthcare setting. Materials and methods: This study was cross-sectional included 111 lean patients diagnosed with NAFLD using either ultrasound or VCTE from January 2023 to March 2024. Anthropometric, laboratory and non-invasive liver fibrosis evaluation parameters were used. The study assessed clinical characteristics and metabolic risk factors of patients with BMI ≤ 23 kg/m2 and BMI between 23 and ≤ 25 kg/m2 using MASLD and MAFLD diagnostic criteria. Results: The cohort included NAFLD patients with a mean age of 43.3 years (±13.2 years). Of the participants, 33% were diagnosed through ultrasonography, whereas 67% diagnosis were made via Fibro scan. Majority were male 92 (83%), while females were 19 (17%) of the entire group. The lean NAFLD criteria for Asia and the West were satisfied by 43 (39%) persons with a BMI ≤ 23 kg/m2 and 68 (61%) individuals with a BMI between 23 and ≤ 25 kg/m2, respectively. The average body mass index (BMI) was 23.0 ± 1.5 kg/m2. Diabetes was observed in 16%, hypertension 11%, and ischemic heart disease in 2%. Out of the total individuals, 92 satisfied the MASLD-MAFLD criteria, whereas 18 did not qualify the MAFLD criteria for diagnosis and were classed as MASLD-Alone. Elevated triglycerides, insulin resistance (HOMA-IR ≥ 2), and three or more cardiometabolic risk factors (CMRF) were significant in the MASLD-MAFLD group compared to the MASLD-Alone group (p < 0.05). Comparing BMI criteria, no significant differences were found in terms of fibrosis between the Western and Asian lean NAFLD BMI criteria's (p = 0.243). Conclusion: Lean NAFLD is a major global health concern. Applying non-Asian BMI criteria (BMI ≤ 25 kg/m2) for lean Asians improves early detection and intervention for at-risk individuals. Accurate use of MAFLD and MASLD criteria is essential to prevent confusion in diagnosing lean NAFLD. Further multicenter investigations with larger sample numbers are required to corroborate these results in our community.

PDF Share
  1. Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology 2023;77(4):1335–1347. DOI: 10.1097/HEP.0000000000000004.
  2. Le MH, Le DM, Baez TC, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. Journal of Hepatology 2023;79(2):287–295. DOI: 10.1016/j.jhep.2023.03.040.
  3. Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clinical Gastroenterology and Hepatology 2021;19(3):580–589. DOI: 10.1016/j.cgh.2020.05.064.
  4. Holmer M, Melum E, Isoniemi H, et al. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. Liver International 2018;38(11):2082–2090. DOI: 10.1111/liv.13751.
  5. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. The lancet Gastroenterology & Hepatology 2020;5(8):739–752. DOI: 10.1016/S2468-1253(20)30 077-7.
  6. Golabi P, Paik JM, AlQahtani S, et al. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. Journal of hepatology. 2021;75(4):795–809. DOI: 10.1016/j.jhep.2021.05.022.
  7. Leung JC, Loong TC, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology 2017;65(1):54–64. DOI: 10.1002/hep.28697.
  8. Younes R, Bugianesi E. NASH in lean individuals. In Seminars in liver disease. New York: Thieme Medical Publishers. 2019;(39)1: pp. 86–95.
  9. Lu FB, Zheng KI, Rios RS, et al. Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of gastroenterology and hepatology. 2020;35(12):2041–2050. DOI: 10.1111/jgh.15156.
  10. Weinberg EM, Trinh HN, Firpi RJ, et al. Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases. Clinical Gastroenterology and Hepatology. 2021;19(5):996–1008.
  11. Cruz AC, Bugianesi E, George J, et al. 379 characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease. Gastroenterology 2014;146(5):S-909. DOI: 10.1016/S0016-5085(14)63307-2.
  12. Tan KC. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The lancet. 2004;363(9403):157–163. DOI: 10.1016/S0140-6736(03) 15268-3.
  13. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Prac 2016;22(Suppl 3):1–203. DOI: 10.4158/EP161365.GL.
  14. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology 2020;73(1):202–209. DOI: 10.1016/j.jhep.2020.03.039.
  15. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023;78(6):1966–1986. DOI: 10.1097/HEP.000000000000 0520.
  16. Lee HW, Park SY, Kim SU, et al. Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease. PloS one 2016;11(6):e0157358. DOI: 10.1371/journal.pone.0157358.
  17. Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian journal of psychological medicine 2013;35(2):121–126. PMID: 24049221.
  18. Ebrahimi F, Hagström H, Sun J, et al. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study. Journal of Hepatology 2023;79(6):1374–1384. DOI: 10.1016/j.jhep.2023.08.018.
  19. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55(6):2005–2023. DOI: 10.1002/hep.25762.
  20. Siddiqui MS, Harrison SA, Abdelmalek MF, et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology 2018;67(5):2001-2012. DOI: 10.1002/hep.29607.
  21. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328–357. DOI: 10.1002/hep.29367.
  22. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol 2017;112(1):18–35. DOI: DOI: 10.1038/ajg.2016.517.
  23. Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158(7):1999–2014. DOI: 10.1053/j.gastro.2019.11.312.
  24. Ghasemi A, Tohidi M, Derakhshan A, et al. Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran Lipid and Glucose Study. Acta diabetologica 2015;52(5):905–915. DOI: 10.1007/s00592-015-0730-3.
  25. Cassinotto C, Boursier J, de Lédinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology. 2016;63(6):1817–1827. DOI: 10.1002/hep.28394.
  26. Singh S, Kuftinec GN, Sarkar S. Non-alcoholic fatty liver disease in South Asians: A review of the literature. Journal of Clinical and Translational Hepatology 2017;5(1):76–81. PMID: 28507930.
  27. Pati GK, Singh SP. Nonalcoholic fatty liver disease in South Asia. Euroasian Journal of Hepato-gastroenterology 2016;6(2):154. DOI: 10.5005/jp-journals-10018-1189.
  28. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. Journal of Hepatology 2017;67(4):862–873. DOI: 10.1016/j.jhep.2017.06.003.
  29. Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: Emerging perspectives. Journal of Gastroenterology 2017;52:164–174. DOI: 10.1007/s00535-016-1264-3.
  30. VanWagner LB, Armstrong MJ. Lean NAFLD: A not so benign condition? Hepatology communications 2018;2(1):5–8. DOI: 10.1002/hep4.1143.
  31. Wei JL, Leung JC, Loong TC, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Official journal of the American College of Gastroenterology ACG. 2015;110(9):1306–1314. DOI: 10.1038/ajg.2015.235.
  32. Lin SU, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver international. 2020;40(9):2082–2089. DOI: 10.1111/liv.14548.
  33. Ramírez-Mejía MM, Jiménez-Gutiérrez C, Eslam M, et al. Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification? Hepatology International 2024;18(1):168–178. DOI: 10.1007/s12072-023-10620-y.
  34. De A, Bhagat N, Mehta M, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD. Journal of hepatology. 2024;80(2):e61–e62. DOI: 10.1016/j.jhep.2023.07.031.
  35. Young S, Tariq R, Provenza J, et al. Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis. Hepatology communications 2020;4(7):953–972. DOI: 10.1002/hep4.1519.
  36. Hill MA, Yang Y, Zhang L, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism 2021;119:154766. DOI: 10.1016/j.metabol.2021.154766.
  37. Narasimhan VM, Patterson N, Moorjani P, et al. The formation of human populations in South and Central Asia. Science 2019;365(6457): eaat7487. DOI: 10.1126/science.aat7487.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.